These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28274625)

  • 1. APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL/6 mice.
    Bahirat UA; Shenoy RR; Goel RN; Nemmani KV
    Eur J Pharmacol; 2017 Apr; 801():35-45. PubMed ID: 28274625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet.
    Bahirat UA; Shenoy RR; Talwar R; Goel RN; Nemmani KVS
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1608-1613. PubMed ID: 29203247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes.
    Bahirat UA; Talwar R; Shenoy RR; Nemmani KVS; Goel RN
    Med Mol Morphol; 2019 Mar; 52(1):36-43. PubMed ID: 29959534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GPR119: a promising target for nonalcoholic fatty liver disease.
    Yang JW; Kim HS; Im JH; Kim JW; Jun DW; Lim SC; Lee K; Choi JM; Kim SK; Kang KW
    FASEB J; 2016 Jan; 30(1):324-35. PubMed ID: 26399788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
    Chu ZL; Carroll C; Alfonso J; Gutierrez V; He H; Lucman A; Pedraza M; Mondala H; Gao H; Bagnol D; Chen R; Jones RM; Behan DP; Leonard J
    Endocrinology; 2008 May; 149(5):2038-47. PubMed ID: 18202141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms.
    Flock G; Holland D; Seino Y; Drucker DJ
    Endocrinology; 2011 Feb; 152(2):374-83. PubMed ID: 21068156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
    Finn PD; Rodriguez D; Kohler J; Jiang Z; Wan S; Blanco E; King AJ; Chen T; Bell N; Dragoli D; Jacobs JW; Jain R; Leadbetter M; Siegel M; Carreras CW; Koo-McCoy S; Shaw K; Le C; Vanegas S; Hsu IH; Kozuka K; Okamoto K; Caldwell JS; Lewis JG
    Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G412-G424. PubMed ID: 30605011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats.
    Matsumoto K; Yoshitomi T; Ishimoto Y; Tanaka N; Takahashi K; Watanabe A; Chiba K
    J Pharmacol Exp Ther; 2018 Dec; 367(3):509-517. PubMed ID: 30217957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Cell Inactivation of
    Panaro BL; Flock GB; Campbell JE; Beaudry JL; Cao X; Drucker DJ
    Diabetes; 2017 Jun; 66(6):1626-1635. PubMed ID: 28254842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic Effects of a GPR119 Agonist with Metformin on Weight Loss in Diet-Induced Obese Mice.
    Al-Barazanji K; McNulty J; Binz J; Generaux C; Benson W; Young A; Chen L
    J Pharmacol Exp Ther; 2015 Jun; 353(3):496-504. PubMed ID: 25770135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stimulating β-cell replication and improving islet graft function by AR231453, A GPR119 agonist.
    Gao J; Tian L; Weng G; O'Brien TD; Luo J; Guo Z
    Transplant Proc; 2011 Nov; 43(9):3217-20. PubMed ID: 22099761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.
    Kim MK; Cheong YH; Lee SH; Kim TH; Jung IH; Chae Y; Lee JH; Yang EK; Park H; Yang JS; Hong KW
    Biomed Pharmacother; 2021 Dec; 144():112324. PubMed ID: 34678732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice.
    Jouihan H; Will S; Guionaud S; Boland ML; Oldham S; Ravn P; Celeste A; Trevaskis JL
    Mol Metab; 2017 Nov; 6(11):1360-1370. PubMed ID: 29107284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exendin-4, a glucagon-like peptide-1 receptor agonist downregulates hepatic receptor for advanced glycation end products in non-alcoholic steatohepatitis rat model.
    Allam MM; El Gazzar WB
    Arch Physiol Biochem; 2018 Feb; 124(1):10-17. PubMed ID: 28696785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.
    Xue H; Xing HJ; Wang B; Fu C; Zhang YS; Qiao X; Guo C; Zhang XL; Hu B; Zhao X; Deng LJ; Zhu XC; Zhang Y; Liu YF
    Drug Des Devel Ther; 2023; 17():1417-1432. PubMed ID: 37197367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.
    Zhou D; Chen YW; Zhao ZH; Yang RX; Xin FZ; Liu XL; Pan Q; Zhou H; Fan JG
    Exp Mol Med; 2018 Dec; 50(12):1-12. PubMed ID: 30510243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.
    Trevaskis JL; Griffin PS; Wittmer C; Neuschwander-Tetri BA; Brunt EM; Dolman CS; Erickson MR; Napora J; Parkes DG; Roth JD
    Am J Physiol Gastrointest Liver Physiol; 2012 Apr; 302(8):G762-72. PubMed ID: 22268099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of long acting GLP1R/GCGR agonist in a DIO and biopsy-confirmed mouse model of NASH suggest a beneficial role of GLP-1/glucagon agonism in NASH patients.
    Monfeuga T; Norlin J; Bugge A; Gaalsgaard ED; Prada-Medina CA; Latta M; Veidal SS; Petersen PS; Feigh M; Holst D
    Mol Metab; 2024 Jan; 79():101850. PubMed ID: 38065435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GPR40 Full Agonist SCO-267 Improves Liver Parameters in a Mouse Model of Nonalcoholic Fatty Liver Disease without Affecting Glucose or Body Weight.
    Ookawara M; Matsuda K; Watanabe M; Moritoh Y
    J Pharmacol Exp Ther; 2020 Oct; 375(1):21-27. PubMed ID: 32719069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.